Novartis and BeiGene bookended 2021 with collaborative deals. In January, Novartis licensed the China-based company’s checkpoint inhibitor, tislelizumab. On December 20, the Swiss pharma giant announced the licensing of the late-stage TIGIT inhibitor ociperlimab to bolster Novartis’ immunotherapy pipeline.
J.P. Morgan Chase put an end to the uncertainty surrounding its annual health care conference, announcing that the 40th edition will move to a virtual format.
Novartis dropped out of the company’s deal to fund Mesoblast’s floundering COVID-19 treatment.
Novartis is going full steam ahead with the company’s cancer development efforts, posting positive results from two ongoing trials for lymphoma and leukemia.
Novartis hopes to still play a role in the development of Covid-19 treatments with ongoing research for a pill that could work broadly against coronaviruses, not just the one that causes Covid-19, chief executive Vas Narasimhan told Reuters.
Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.
Shares of Xencor were down nearly 6 percent after announcing Novartis terminated the company’s rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific, which was part of a 2016 collaboration valued at $2.6 billion.
For the past 20 years, Novartis has held a 33 percent stake in Roche, the company’s Basel, Switzerland neighbor. Now, Novartis has divested the Swiss drugmaker’s one-third stake to Roche for $20.7 billion.
Novartis forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
The U.S. Food and Drug Administration approved Novartis’ first-in-class Scemblix (asciminib) for two indications in the treatment of chronic myeloid leukemia (CML).
